Creates provisions relating to abuse-deterrent opioid analgesic drug products

HB 1118 requires health insurance plans to cover at least one abuse-deterrent opioid analgesic drug per active ingredient, ensuring patients have access to formulations designed to reduce misuse. It limits patient cost-sharing (like copays) for these drugs to the same level as non-abuse-deterrent opioids, preventing higher out-of-pocket costs. The bill also prohibits insurers from denying coverage or requiring prior authorization for abuse-deterrent opioids based on the need to first try non-abuse-deterrent alternatives. This directly affects insurance companies, patients prescribed opioids for pain, and healthcare providers.